This is intriguing to me: “We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update....”
RXMD didn’t just eclipse the .10 target, they blew right thru it! If history repeats itself, we should be sitting at or near $.50 soon. IMHO
Well I see seethru has finally come to the same conclusion I came to of .35 pps two weeks ago and again that is based on probable 2017 numbers to be confirmed 03/31. The valuation will go to over .50 when new acquisition is confirmed and a dollar by year end for certain but of course all IMO
Great News! $.35 price target! But important to point out this does not include or mention the additional new location. Only mentions the out-of-state licenses expansion. Which makes sense since we dont officially have that location yet. Good luck investors.